Painreform Ltd (PRFX) Fair Value & Analysis
Healthcare · US · Market cap $5.0M · ISIN IL0011651580
What is Painreform Ltd really worth?
Painreform Ltd
PRFX · US
Below-average quality, and trading another 273% above our fair value of $0.2550.
Risks
Fair value as of: Aug 13, 2026
From 1 valuation models · updated 19 days ago
Share price −4.9% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case ($0.3145). The favourable scenario is already priced in.
- Weak quality (34/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range ($0.1700 to $0.3145) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range $0.9417 – $4,896 · fair‑value band $0.1700 – $0.3145 · the $0.9512 price screens above the $0.2550 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Painreform Ltd (PRFX) currently trades at $0.9512, while our model-based Fair Value estimate is $0.2550, implying the stock looks roughly 273.0% overvalued today. The Quality Score stands at 34/100 (below-average quality), in the Healthcare sector. How firm this estimate is: it rests on 1 models at a data quality of 85/100, which puts the evidence level at low.
Trailing-twelve-month revenue stands at $17.0K. It earns a return on equity of −90.4%. The balance sheet holds a net cash position of $4.1M. Fundamentals as of Aug 13, 2026
Our scenario range runs from $0.1700 (bear case) to $0.3145 (bull case); at $0.9512, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −73%, PRFX screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 1 models by family
Notify me when PRFX reaches fair value
Put PRFX on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 36 · Market factors (momentum, volatility) 9
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
PRF Technologies Ltd., a specialty pharmaceutical company, focuses on reformulation of established therapeutics in Israel.
Full company description
PRF Technologies Ltd., a specialty pharmaceutical company, focuses on reformulation of established therapeutics in Israel. It develops OcuRing-K, a bio-erodible sustained-release implant applied to the haptic of an intraocular lens for use in cataract surgery; and PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company was formerly known as PainReform Ltd. and changed its name to PRF Technologies Ltd. in January 2026. PRF Technologies Ltd. was incorporated in 2007 and is based in Tel Aviv-Yafo, Israel.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Painreform Ltd reported revenue of $17.0K in FY2025 versus $0 in FY2021. Reported net income was −$4.8M in FY2025.
PRFX screens 273% overvalued. Compare with Merck KGaA →
Peer Group
Drug Manufacturers - Specialty & Generic · 635 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Merck KGaA MRK | €140.25 | €106.48 | −24% |
| Takeda Pharmaceutical Company TAK | $18.03 | $11.11 | −38% |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.76 | ¥25.94 | −52% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | −49% |
| Galderma Group GALD | CHF 178.55 | CHF 55.07 | −69% |
| Haleon plc HLN | $10.11 | $7.64 | −24% |
| Teva Pharmaceutical Industries Limited TEVA | $36.05 | $15.33 | −57% |
| Sandoz Group SDZ | CHF 70.66 | CHF 39.21 | −45% |
| Zoetis Inc ZTS | $77.10 | $104.88 | +36% |
| Hansoh Pharmaceutical Group 3692 | HK$33.50 | HK$16.14 | −52% |
Compare Painreform Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Painreform Ltd (PRFX) overvalued or undervalued?
What is the fair value of PRFX?
What is the quality score of PRFX?
What is the revenue of Painreform Ltd (PRFX)?
What is the net profit margin of PRFX?
Watch Painreform Ltd in the live analysis
One click puts Painreform Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.